Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer

ABSTRACT Immune checkpoint inhibitors (ICI), have transformed the management of several types of cancers; however, immune‐related adverse events (irAEs) may cause treatment interruptions, chronic toxic effects, and death. Elderly patients are at high risk of cancer. Compared with traditional chemoth...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiayi Gao, Yue Yuan, Xue Wang, Liuer He, Lin Li
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:Aging Medicine
Subjects:
Online Access:https://doi.org/10.1002/agm2.70000
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850204818700763136
author Jiayi Gao
Yue Yuan
Xue Wang
Liuer He
Lin Li
author_facet Jiayi Gao
Yue Yuan
Xue Wang
Liuer He
Lin Li
author_sort Jiayi Gao
collection DOAJ
description ABSTRACT Immune checkpoint inhibitors (ICI), have transformed the management of several types of cancers; however, immune‐related adverse events (irAEs) may cause treatment interruptions, chronic toxic effects, and death. Elderly patients are at high risk of cancer. Compared with traditional chemotherapy, immunotherapy has become a better alternative choice for elderly patients with cancer due to its high efficiency and low toxicity. However, the emergence of immunosenescence accompanied by advancing age raises safety concerns for ICI. Therefore, we summarize the characteristics of irAEs occurred in elderly patients with cancer and the physiological characteristics of immunosenescence, which will lay a theoretical foundation for the safety management of immunotherapy in elderly patients with cancer.
format Article
id doaj-art-c3dfdbc79c214875b87372f4150ef1ce
institution OA Journals
issn 2475-0360
language English
publishDate 2025-02-01
publisher Wiley
record_format Article
series Aging Medicine
spelling doaj-art-c3dfdbc79c214875b87372f4150ef1ce2025-08-20T02:11:13ZengWileyAging Medicine2475-03602025-02-0181n/an/a10.1002/agm2.70000Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With CancerJiayi Gao0Yue Yuan1Xue Wang2Liuer He3Lin Li4Department of Oncology, Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing People's Republic of ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing People's Republic of ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing People's Republic of ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing People's Republic of ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology Institute of Geriatric Medicine, Chinese Academy of Medical Sciences Beijing People's Republic of ChinaABSTRACT Immune checkpoint inhibitors (ICI), have transformed the management of several types of cancers; however, immune‐related adverse events (irAEs) may cause treatment interruptions, chronic toxic effects, and death. Elderly patients are at high risk of cancer. Compared with traditional chemotherapy, immunotherapy has become a better alternative choice for elderly patients with cancer due to its high efficiency and low toxicity. However, the emergence of immunosenescence accompanied by advancing age raises safety concerns for ICI. Therefore, we summarize the characteristics of irAEs occurred in elderly patients with cancer and the physiological characteristics of immunosenescence, which will lay a theoretical foundation for the safety management of immunotherapy in elderly patients with cancer.https://doi.org/10.1002/agm2.70000elderly patientsimmune checkpoint inhibitorsimmune‐related adverse eventsimmunosenescence
spellingShingle Jiayi Gao
Yue Yuan
Xue Wang
Liuer He
Lin Li
Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer
Aging Medicine
elderly patients
immune checkpoint inhibitors
immune‐related adverse events
immunosenescence
title Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer
title_full Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer
title_fullStr Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer
title_full_unstemmed Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer
title_short Impact of Immunosenescence on Immune‐Related Adverse Events in Elderly Patients With Cancer
title_sort impact of immunosenescence on immune related adverse events in elderly patients with cancer
topic elderly patients
immune checkpoint inhibitors
immune‐related adverse events
immunosenescence
url https://doi.org/10.1002/agm2.70000
work_keys_str_mv AT jiayigao impactofimmunosenescenceonimmunerelatedadverseeventsinelderlypatientswithcancer
AT yueyuan impactofimmunosenescenceonimmunerelatedadverseeventsinelderlypatientswithcancer
AT xuewang impactofimmunosenescenceonimmunerelatedadverseeventsinelderlypatientswithcancer
AT liuerhe impactofimmunosenescenceonimmunerelatedadverseeventsinelderlypatientswithcancer
AT linli impactofimmunosenescenceonimmunerelatedadverseeventsinelderlypatientswithcancer